Literature DB >> 11559832

Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries.

F Bugli1, N Mancini, C Y Kang, C Di Campli, A Grieco, A Manzin, A Gabrielli, A Gasbarrini, G Fadda, P E Varaldo, M Clementi, R Burioni.   

Abstract

Clinical and experimental evidence indicates that the hepatitis C virus (HCV) E2 glycoprotein (HCV/E2) is the most promising candidate for the development of an effective anti-HCV vaccine. Identification of the human epitopes that are conserved among isolates and are able to elicit protective antibodies would constitute a significant step forward. This work describes the mapping of the B-cell epitopes present on the surface of HCV/E2, as recognized by the immune system during infection, by the analysis of the reciprocal interactions of a panel of human recombinant Fabs derived from an HCV-infected patient. Three unrelated epitopes recognized by antibodies with no neutralization-of-binding (NOB) activity were identified; a fourth, major epitope was defined as a clustering of minor epitopes recognized by Fabs endowed with strong NOB activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559832      PMCID: PMC114571          DOI: 10.1128/JVI.75.20.9986-9990.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Human monoclonal recombinant Fabs specific for HCV antigens obtained by repertoire cloning in phage display combinatorial vectors.

Authors:  P Plaisant; R Burioni; A Manzin; L Solforosi; M Candela; A Gabrielli; G Fadda; M Clementi
Journal:  Res Virol       Date:  1997 Mar-Apr

2.  Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial.

Authors:  M Piazza; L Sagliocca; G Tosone; V Guadagnino; M A Stazi; R Orlando; G Borgia; D Rosa; S Abrignani; F Palumbo; A Manzin; M Clementi
Journal:  Arch Intern Med       Date:  1997-07-28

3.  Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments.

Authors:  R Burioni; P Plaisant; A Manzin; D Rosa; V Delli Carri; F Bugli; L Solforosi; S Abrignani; P E Varaldo; G Fadda; M Clementi
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

4.  Murine humoral immune response against recombinant structural proteins of hepatitis C virus distinct from those of patients.

Authors:  M Ahmed; T Shikata; M Esumi
Journal:  Microbiol Immunol       Date:  1996       Impact factor: 1.955

5.  A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.

Authors:  D Rosa; S Campagnoli; C Moretto; E Guenzi; L Cousens; M Chin; C Dong; A J Weiner; J Y Lau; Q L Choo; D Chien; P Pileri; M Houghton; S Abrignani
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

6.  Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection.

Authors:  A Manzin; L Solforosi; M Debiaggi; F Zara; E Tanzi; L Romanò; A R Zanetti; M Clementi
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 7.  Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.

Authors:  A Cerny; F V Chisari
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

8.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

9.  Identification of a domain containing B-cell epitopes in hepatitis C virus E2 glycoprotein by using mouse monoclonal antibodies.

Authors:  J W Lee; K m Kim; S H Jung; K J Lee; E C Choi; Y C Sung; C Y Kang
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.

Authors:  K Ishii; D Rosa; Y Watanabe; T Katayama; H Harada; C Wyatt; K Kiyosawa; H Aizaki; Y Matsuura; M Houghton; S Abrignani; T Miyamura
Journal:  Hepatology       Date:  1998-10       Impact factor: 17.425

View more
  27 in total

Review 1.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Identification of a novel B cell epitope on the nucleocapsid protein of porcine reproductive and respiratory syndrome virus by phage display.

Authors:  Tong-Qing An; Yan-Jun Zhou; Hua-Ji Qiu; Guang-Zhi Tong; Yun-Feng Wang; Jin-Xia Liu; Jin-Yu Yang
Journal:  Virus Genes       Date:  2005-08       Impact factor: 2.332

3.  Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.

Authors:  Mario Perotti; Nicasio Mancini; Roberta A Diotti; Alexander W Tarr; Jonathan K Ball; Ania Owsianka; R Adair; Arvind H Patel; Massimo Clementi; Roberto Burioni
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

4.  Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Authors:  Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Yong Wang; Patrick Lau; Thomas Krey; Felix A Rey; Steven K H Foung
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

5.  Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype.

Authors:  Roberto Burioni; Yoshiharu Matsuura; Nicasio Mancini; Hideki Tani; Tatsuo Miyamura; Pietro E Varaldo; Massimo Clementi
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Authors:  Nicasio Mancini; Roberta A Diotti; Mario Perotti; Giuseppe Sautto; Nicola Clementi; Giovanni Nitti; Arvind H Patel; Jonathan K Ball; Massimo Clementi; Roberto Burioni
Journal:  PLoS One       Date:  2009-12-11       Impact factor: 3.240

8.  In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.

Authors:  Meital Gal-Tanamy; Zhen-Yong Keck; MinKyung Yi; Jane A McKeating; Arvind H Patel; Steven K H Foung; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-03       Impact factor: 11.205

Review 9.  HCV E2 core structures and mAbs: something is still missing.

Authors:  Matteo Castelli; Nicola Clementi; Giuseppe A Sautto; Jennifer Pfaff; Kristen M Kahle; Trevor Barnes; Benjamin J Doranz; Matteo Dal Peraro; Massimo Clementi; Roberto Burioni; Nicasio Mancini
Journal:  Drug Discov Today       Date:  2014-08-27       Impact factor: 7.851

10.  Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.

Authors:  Ania M Owsianka; Alexander W Tarr; Zhen-Yong Keck; Ta-Kai Li; Jeroen Witteveldt; Richard Adair; Steven K H Foung; Jonathan K Ball; Arvind H Patel
Journal:  J Gen Virol       Date:  2008-03       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.